Advanced stage melanoma therapies: Detailing the present and exploring the future. (January 2019)

• Record Type: Journal Article
• Authors: Luther, Chelsea; Swami, Umang; Zhang, Jun; Milhem, Mohammed; Zakharia, Yousef
• Is Part Of: Critical reviews in oncology/hematology. Volume 133(2019)
• Page Start: 99
• Page End: 111
• Publication Date: 2019-01
• Subjects: MM metastatic melanoma -- ORR overall response rate -- FDA Food and Drug Administration -- GITR glucocorticoid-induced tumor necrosis factor-related gene receptor -- mAb monoclonal antibody -- CTLA-4 cytotoxic T-lymphocyte-associated antigen-4 -- APCs antigen-presenting cells -- gp100 glycoprotein 100 -- OS overall survival -- DOR prolonged duration of response -- AEs adverse effects -- MAPK mitogen-activated protein kinase -- ERK extracellular-signal-regulated kinase -- SCC squamous cell carcinoma -- PD-1 programmed death 1 -- TVEC talimogene Laherparepvec -- HSV1 herpes-simplex-1 -- GM-CSF granulocyte-macrophage colony-stimulating factor -- COT Cancer Osaka Thyroid -- CDKN2A Cyclin-Dependent Kinase Inhibitor 2A -- DLTs dose-limiting toxicities -- DCR disease-control rate -- ALT alanine aminotransferase -- AST aspartate aminotransferase -- GGT gamma-glutamyl transferase -- CPK creatine phosphokinase -- TNFRSF TNF receptor super family -- Tim-3 T-cell immunoglobulin and mucin containing protein-3 -- IDO indoleamine 2, 3-dioxygenase -- TDO tryptophan 2, 3-dioxygenase -- AHR aryl-hydrocarbon receptor -- CpG cytosine guanine dinucleotide -- ODN oligodeoxyneucelotides -- pDC plamacytoid dendritic cells -- MTD maximum tolerated dose -- CRS cytokine release syndrome -- LAG-3 Lymphocyte activation gene-3 -- NSCLC non-small cell lung cancer -- RCC renal cell carcinoma -- MAP2 microtubule-associated protein; Metastatic melanoma -- Immunotherapy -- Targeted therapy -- Combination therapy -- CTLA-4 -- PD1 -- BRAF -- Ipilimumab -- Vemurafenib -- Dabrafenib -- Nivolumab -- Pembrolizumab -- MEDI4736 -- Talimogene -- TVEC -- Indoleamine 2, 3-dioxygenase -- Indoximod (D-1MT) -- Epacadostat; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2018.11.002
• Languages: English
• ISSNs: 1040-8428

Abstract

Abstract: Metastatic melanoma therapies have proliferated over the last ten years. Prior to this, decades passed with only very few drugs available to offer our patients, and even then, those few drugs had minimal survival benefits. Many treatment options emerged over the last ten years with diverse mechanisms of action. Further, combination regimens have demonstrated superiority over monotherapy, especially for targeted agents. Each therapeutic combination possesses different advantages and side effect profiles. In this review, we outline the United States Food and Drug Administration–approved melanoma treatment agents and therapies currently in clinical development, focusing on combination approaches.